Tags

Type your tag names separated by a space and hit enter

Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.
Biochem Biophys Res Commun. 2007 Apr 27; 356(1):53-9.BB

Abstract

Dietary model of steatohepatitis was established by feeding mice a methionine choline deficient (MCD) diet. Mice on MCD or control diet for 3 weeks were treated with or without NO-1886, a newly synthetic lipoprotein lipase (LPL) activator. In a separate experiment, NO-1886 was given after pre-treatment with 3 weeks of MCD diet. NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). In addition, NO-1886 dampened hepatic steatosis via accelerating fatty acid oxidation caused by enhanced expression of PPARalpha, cytochrome P450-10 (Cyp4a10), and Acyl-CoA oxidase (ACO). It failed to regulate genes of fatty acid uptake and synthesis pathways. In conclusion, NO-1886 ameliorated and induced regression of experimental steatohepatitis via increasing endogenous LPL activation resulting in suppression on pro-inflammatory factors and reduction of hepatic fatty acids. These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis.

Authors+Show Affiliations

Institute of Digestive Disease, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17350593

Citation

Yu, Jun, et al. "Lipoprotein Lipase Activator Ameliorates the Severity of Dietary Steatohepatitis." Biochemical and Biophysical Research Communications, vol. 356, no. 1, 2007, pp. 53-9.
Yu J, Chu ES, Hui AY, et al. Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. Biochem Biophys Res Commun. 2007;356(1):53-9.
Yu, J., Chu, E. S., Hui, A. Y., Cheung, K. F., Chan, H. L., Leung, W. K., Farrell, G. C., & Sung, J. J. (2007). Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. Biochemical and Biophysical Research Communications, 356(1), 53-9.
Yu J, et al. Lipoprotein Lipase Activator Ameliorates the Severity of Dietary Steatohepatitis. Biochem Biophys Res Commun. 2007 Apr 27;356(1):53-9. PubMed PMID: 17350593.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis. AU - Yu,Jun, AU - Chu,Eagle S H, AU - Hui,Alex Y, AU - Cheung,Kin F, AU - Chan,Henry L Y, AU - Leung,Wai K, AU - Farrell,Geoffrey C, AU - Sung,Joseph J Y, Y1 - 2007/03/05/ PY - 2007/02/15/received PY - 2007/02/16/accepted PY - 2007/3/14/pubmed PY - 2007/6/21/medline PY - 2007/3/14/entrez SP - 53 EP - 9 JF - Biochemical and biophysical research communications JO - Biochem. Biophys. Res. Commun. VL - 356 IS - 1 N2 - Dietary model of steatohepatitis was established by feeding mice a methionine choline deficient (MCD) diet. Mice on MCD or control diet for 3 weeks were treated with or without NO-1886, a newly synthetic lipoprotein lipase (LPL) activator. In a separate experiment, NO-1886 was given after pre-treatment with 3 weeks of MCD diet. NO-1886 significantly reduced MCD-induced inflammation by repressing levels of hepatic lipid peroxides and pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2). In addition, NO-1886 dampened hepatic steatosis via accelerating fatty acid oxidation caused by enhanced expression of PPARalpha, cytochrome P450-10 (Cyp4a10), and Acyl-CoA oxidase (ACO). It failed to regulate genes of fatty acid uptake and synthesis pathways. In conclusion, NO-1886 ameliorated and induced regression of experimental steatohepatitis via increasing endogenous LPL activation resulting in suppression on pro-inflammatory factors and reduction of hepatic fatty acids. These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis. SN - 0006-291X UR - https://www.unboundmedicine.com/medline/citation/17350593/Lipoprotein_lipase_activator_ameliorates_the_severity_of_dietary_steatohepatitis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-291X(07)00367-1 DB - PRIME DP - Unbound Medicine ER -